Back to today’s briefing

Story perspectives

FDA Fast-Tracks Innovative Cancer Therapies, Igniting Patient Hope

3/4/2025

23 5

Summary

Story summary

In a groundbreaking move, the FDA fast-tracked several promising cancer therapies in February 2025, including amezalpat for liver cancer and rapamycin for adenomatous polyposis. This pivotal moment also saw gene therapies like Regeneron's DB-OTO and Ultragenyx's UX111 for Sanfilippo syndrome gain crucial regulatory support, igniting hope for patients battling these challenging conditions.

1 of 1

Story summary

In a groundbreaking move, the FDA fast-tracked several promising cancer therapies in February 2025, including amezalpat for liver cancer and rapamycin for adenomatous polyposis. This pivotal moment also saw gene therapies like Regeneron's DB-OTO and Ultragenyx's UX111 for Sanfilippo syndrome gain crucial regulatory support, igniting hope for patients battling these challenging conditions.